Novartis AG (NYSE:NVS) released its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.06, RTT News reports. The company had revenue of $12.24 billion for the quarter, compared to analyst estimates of $12.20 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The company’s revenue was down 1.8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.23 EPS.
Shares of Novartis AG (NVS) traded down 0.42% during midday trading on Monday, reaching $84.61. 315,616 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $83.64 and a 200 day moving average price of $78.07. Novartis AG has a 12 month low of $66.93 and a 12 month high of $86.90. The firm has a market cap of $198.23 billion, a PE ratio of 30.89 and a beta of 0.73.
ILLEGAL ACTIVITY NOTICE: “Novartis AG (NYSE:NVS) Releases Quarterly Earnings Results” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://stocknewstimes.com/2017/08/07/novartis-ag-nysenvs-posts-earnings-results-beats-estimates-by-0-06-eps-updated-updated.html.
In related news, major shareholder Bioventures Ltd Novartis purchased 266,667 shares of Novartis AG stock in a transaction dated Wednesday, July 5th. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $4,000,005.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.01% of the company’s stock.
Several institutional investors have recently bought and sold shares of NVS. Moreno Evelyn V increased its position in Novartis AG by 15.3% in the first quarter. Moreno Evelyn V now owns 87,015 shares of the company’s stock valued at $6,463,000 after buying an additional 11,520 shares during the period. Rosenbaum Jay D. increased its position in Novartis AG by 26.7% in the first quarter. Rosenbaum Jay D. now owns 4,745 shares of the company’s stock valued at $352,000 after buying an additional 1,000 shares during the period. Cohen Lawrence B increased its position in Novartis AG by 17.2% in the first quarter. Cohen Lawrence B now owns 25,788 shares of the company’s stock valued at $1,915,000 after buying an additional 3,780 shares during the period. First Financial Bank N.A. Trust Division increased its stake in Novartis AG by 16.6% in the first quarter. First Financial Bank N.A. Trust Division now owns 4,394 shares of the company’s stock worth $327,000 after buying an additional 625 shares during the last quarter. Finally, Park National Corp OH increased its stake in Novartis AG by 5.4% in the first quarter. Park National Corp OH now owns 294,860 shares of the company’s stock worth $21,899,000 after buying an additional 15,119 shares during the last quarter. Institutional investors and hedge funds own 11.27% of the company’s stock.
Several research firms have issued reports on NVS. Leerink Swann reaffirmed a “market perform” rating and set a $83.00 price objective on shares of Novartis AG in a report on Thursday, June 22nd. BidaskClub downgraded Novartis AG from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Morgan Stanley raised Novartis AG from an “underweight” rating to an “overweight” rating in a research note on Wednesday, July 26th. Credit Suisse Group cut shares of Novartis AG from a “neutral” rating to an “underperform” rating and set a $82.25 price objective for the company. in a research report on Wednesday, July 5th. Finally, Cowen and Company restated a “hold” rating on shares of Novartis AG in a research report on Tuesday, July 18th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $81.71.
Novartis AG Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.
